OLeary et al., using diagnostic codes, found that GLP-1 RA (exenatide, lixisenatide, semaglutide, dulaglutide, liraglutide, tirzepatide) use was associated with a reduction in the odds of visual loss: at 6 months, OR 0.423 (95% CI 0.3240.546), and at 1 year, OR 0.606 (0.4890.747), compared to matched controls [37]
Slowing gastric emptying to improve satiety
The proliferation of ACV and GLP-1positioned supplements highlight the opportunityand the competitionas new brands enter the market and established brands like Bragg lean into a category increasingly shaped by GLP-1-driven demand.
Identity verification via mass spectrometry confirms correct molecular weight of 4113.58 g/mol
Reduced irritation may improve range of motion and exercise execution
These adjustments are temporary and generally resolve within the first week as your body establishes a new baseline